as well as the use of irradiated blood products and more intensive pretransplant immunosuppression. 2 Two major types of graft rejection occur after BMT for SAA. In pri-A 19-year-old male underwent allogeneic BMT for severe aplastic anaemia (SAA) from his HLA-and blood mary graft failure there is no evidence of engraftment or hematologic recovery of donor cells. Late graft failure is group-identical sister. He was conditioned with cyclophosphamide (CY) and single fraction total lymphoid commonly associated with the emergence of cells of recipient origin, a state of mixed chimerism. The prognosis of irradiation (TLI). GVHD prophylaxis consisted of FK506 and a short course of methotrexate. The patient primary graft failure is poor, particularly for patients who are retransplanted within 60 days.
failed to achieve durable trilineage hematopoietic engraftment. There was no significant myeloid response to GM-CSF or G-CSF. Evaluation of FACS-sorted peripheral T cells from the patient by fluorescence in situ
Case report hybridization (FISH) revealed mixed chimerism (44% host origin). Fifty-three days after the first BMT, he was A 19-year-old Caucasian male with a diagnosis of SAA underwent an allogeneic BMT from his HLA-and ABOtreated with G-CSF primed, unmanipulated PBSC transfusions (5.28 × 10 8 /kg mononuclear, 4.28 × 10 6 /kg identical 18-year-old sister. Prior to this, he had received irradiated leukodepleted blood products for 2 months. Both CD34 + , 292.51 × 10 6 /kg CD3 + cells) from his original donor without reconditioning. FK506 was continued at the patient and the donor were CMV seronegative. The conditioning regimen included CY 50 mg/kg i.v. on each of 4 the same dose. Neutrophil recovery to 0.5 × 10 9 /l and platelet engraftment to 20 × 10 9 /l was achieved 11 and successive days (days −6, −5, −4, −3) and 750 cGy single fraction TLI on day −1. /l and 0.180 × 10 9 /l respectively, BM cellularity identical siblings is the treatment of choice in young Ͻ5% by day +35). GM-CSF was changed to G-CSF at a patients with severe aplastic anemia (SAA).
1 In the past, dose of 10 g/kg/day s.c. daily on day +37 without clinical high rates of graft rejection complicated BMT in patients improvement of graft function. On day +46, the patient's with SAA. The incidence of graft rejection has been declinperipheral blood T cells (CD3 + CD16/CD56 − ) and NK cells ing since 1980 (from 32% to 5%), because of earlier utiliz-(CD3 − CD16/CD56 + ) were sorted. FISH evaluation of the ation of BMT and avoidance of pretransplant transfusions, sorted cells revealed that 44% of the circulating T and 5% of NK cells were still of recipient origin. The same donor was then treated with 10 g G-CSF s.c. The rapid and sustained engraftment, along with the presence of mostly donor origin CD3
+ lymphocytes in the per-PBSC collection was transfused to the patient immediately, without further processing. The patient did not receive any ipheral blood after the G-CSF mobilized PBSC transplant, implies that a large number of donor origin T cells can additional conditioning. He continued to receive i.v. FK506 at the same dose given initially. The absolute neutrophil overcome the residual host origin T lymphocytes even without a prior conditioning regimen. 12 Avoiding reconcount reached Ͼ0.5 × 10 9 /l and Ͼ1 × 10 9 /l on the 11th and 12th day respectively, and the platelet count was ditioning may be important for patients who require a second transplant within 60 days, when toxicity from Ͼ20 × 10 9 /l on the 27th day after the first dose of allogeneic PBSC transfusion. G-CSF was discontinued on the additional chemotherapy or irradiation would be greater.
13
This case indicates that G-CSF mobilized PBSC trans13th day. There was no evidence of acute GVHD. FISH test on sorted peripheral T cells on the 28th day revealed plants without prior conditioning might be a feasible and safe treatment for patients with primary graft failure after that 91% of T cells were of donor origin. A bone marrow biopsy on day 55 showed trilineage engraftment. The BMT for SAA. It remains to be seen if our patient will experience late graft rejection. patient is currently well with a stable engraftment 6 months following rescue allogeneic PBSC transfusions, with no signs of chronic GVHD.
hood of successful second sustained engraftment. phocytes, and the number of transplanted donor origin The early results of allogeneic BMT using G-CSF mobil- As with other investigators, we found a much higher 
